19 results about "Cytarabine" patented technology

The invention discloses a combined pharmaceutical composition for preventing, relieving or treating acute myelogenous leukemia and application, and relates to the technical field of biomedicine. The invention provides a combined pharmaceutical composition for preventing, relieving or treating acute myelogenous leukemia. The combined pharmaceutical composition comprises vincristine and cytarabine or pharmaceutically acceptable salts and solvates of the vincristine and the cytarabine. According to the vincristine and cytarabine combined pharmaceutical composition, the apoptosis level of acute myelogenous leukemia cells can be remarkably improved, and compared with single-drug treatment, the vincristine and cytarabine combined pharmaceutical composition has higher anti-tumor efficacy; vincristine interferes or blocks a cell senescence state induced by cytarabine through a microtubule destruction effect, so that the problem of drug insensitivity caused by cell senescence is solved, and drug resistance caused by cell senescence is effectively reversed.

Compounds of the formula Iwherein X is a bond or —CH2, and pharmaceutically acceptable salts thereof are useful in the parenteral treatment of leukemia, myelodysplastic syndrome or lymphoma, especially in patients presenting with cytarabine resistance and / or over 60 years of age.

The invention discloses a cytarabine syndrome risk prediction model, a training method thereof and a system adopting the same. The model training method comprises the following steps: constructing an artificial intelligence model; wherein the input of the artificial intelligence model comprises the weight and the heating duration of the to-be-evaluated object; the output of the artificial intelligence model is the risk probability that the to-be-evaluated object belongs to the cytarabine syndrome fever; large sample data are adopted to train the artificial intelligence model, cases with fever of the cytarabine syndrome are positive samples, and other fever cases are negative samples. According to the present invention, the identification standard of the cytarabine syndrome fever and the infected fever is established, and the risk probability of the cytarabine syndrome of the object to be evaluated can be evaluated by analyzing the difference of the two detection results in the laboratory, such that the unreasonable use of the antibacterial agent is reduced, the medical cost is reduced, and the drug resistance risk of the antibacterial agent is reduced.

The present invention relates to the use of cytarabine, a mitochondrial metabolism inhibitor and an agent that downregulates the expression or activity of CDA in the treatment of cancer.

The application relates to a pharmaceutical cocrystal of cytarabine and 5-fluorouracil and a preparation method thereof, and relates to the technical field of pharmaceutical cocrystals. The pharmaceutical cocrystal is composed of one cytarabine molecule and one 5-fluorouracil molecule as a basic structural unit, and has a chemical formula of [C9H 13 N3O5.C4H3N2O2F]; the pharmaceutical cocrystal belongs to an orthorhombic system and has a space group of P212121. The pharmaceutical cocrystal prepared by a solvent evaporation method and a cooling method improves the permeability of cytarabine, appropriately reduces the solubility of cytarabine, and significantly improves the antitumor activity of cytarabine; through the complementary advantages of the properties and the pharmacodynamic effects of two components, the synergistic antitumor effects of cytarabine and 5-fluorouracil are realized, and a new idea is provided for developing synergistic antitumor pharmaceutical cocrystals. The pharmaceutical cocrystal can keep the skeleton structure of the crystal unchanged after long-term placement at room temperature, the preparation method is simple and easy to implement, the cost is low, and the pharmaceutical cocrystal is convenient for large-scale production.

The application provides an application of a TRIM44 expression inhibitor in preparation of a cytarabine-resistant leukemia drug, and belongs to the technical field of bioengineering.The application provides the application of the TRIM44 expression inhibitor in preparation of the cytarabine-resistant leukemia drug.In the application, a key gene TRIM44 affecting AML drug resistance is identified by analyzing a single cell transcriptome data set, the expression of the TRIM44 can be lowered by using sinomenine, the function of regulatory T cells (T-reg cells) is inhibited, the sensitivity of AML cells to a chemotherapy drug is enhanced, a good synergistic treatment effect with cytarabine is shown, the cytarabine resistance of leukemia is reversed, and a new target site and a molecular marker are provided for predicting and improving the treatment effect of patients in clinic.

The invention relates to compositions and methods for treating patients with hematological proliferative disorders who are ineligible for treatment with standard intensive chemotherapy, using low intensity treatment with CPX-351, a liposomal composition of daunorubicin and cytarabine.

This invention relates to the use of cytarabine, mitochondrial metabolism inhibitors, and agents that downregulate the expression or activity of CDA in the treatment of cancer.

The invention discloses an application of curcumin in improving puberty male reproductive capacity damage caused by chemotherapeutic drugs. Aiming at the problems of testicular germ cell quantity reduction, oxidative stress injury, long-term fertility damage and the like caused by cytosine arabinoside chemotherapy, curcumin is applied while or before the cytosine arabinoside is applied. The application is realized through combined administration or a pharmaceutical composition containing curcumin and cytarabine. Experiments show that the scheme can effectively relieve testicular tissue form damage, reduce germ cell apoptosis and antagonize oxidative stress, and significantly improve the sperm quality of adult individuals. The invention provides a new potential strategy for synchronously protecting the reproductive function of a clinical child tumor patient during chemotherapy.

The invention provides application of the cytarabine combined immune checkpoint inhibitor in glioma treatment, experiments prove that the cytarabine combined immune checkpoint inhibitor has a synergistic effect on glioma treatment, and the anti-tumor effect of the cytarabine can be enhanced by the cytarabine combined immune checkpoint inhibitor; the lifetime of the mouse is obviously prolonged, and a new strategy is provided for treating glioma.

The invention discloses application of brutinib and a combined pharmaceutical composition thereof in treatment of leukemia, and the leukemia comprises acute myelogenous leukemia, chronic myelogenous leukemia, T acute lymphoblastic leukemia and B acute lymphoblastic leukemia. The invention creatively finds that the brutinib has a remarkable synergistic effect on treatment of the leukemia when being combined with the vinca, the cytarabine or the daunorubicin for use, and a brand new drug combination scheme provided by the invention provides a more effective drug combination choice for treatment of the leukemia, and is expected to improve the treatment effect of patients with the leukemia.

Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

The invention relates to compositions and methods for treating patients with hematological proliferative disorders with CPX-351, a liposomal composition of daunorubicin and cytarabine, and venetoclax.

The invention relates to the technical field of biological medicines, and provides application of a BCAA inhibitor in preparation of medicines for inhibiting, preventing, relieving or treating mutant leukemia aiming at the problems of high drug resistance, high recurrence rate and limited treatment effect in treatment of DNMT3A mutant AML patients at present. The BCAA inhibitor is gabapentin and / or cytarabine arabinoside. Experiments prove that gabapentin has a treatment effect on DNMT3A mutated acute myelogenous leukemia, meanwhile, it is found that DNMT3A mutated acute myelogenous leukemia cells have drug resistance to cytarabine, and the gabapentin and the cytarabine are combined to have a synergistic effect on the DNMT3A mutated acute myelogenous leukemia. The discovery of the application provides a new thought and direction for treatment of mutant leukemia, especially acute myelogenous leukemia with DNMT3A mutation.

This invention relates to the field of pharmaceutical application technology, specifically a method for preparing and applying a vincristine derivative-antibody conjugate. It involves a composition of a small molecule compound represented by general formula (I), a linker (L), and an antibody (Ab), wherein the small molecule compound is a vincristine derivative, which is conjugated to a targeting antibody via the linker to form an ADC drug with significant antitumor activity. Experiments show that this type of ADC exhibits excellent therapeutic effects in a mouse model of acute myeloid leukemia (AML), with efficacy significantly superior to first-line clinical treatment regimens (such as cytarabine combined with veneclade) and traditional vincristine monotherapy. The ADC provided by this invention has the characteristics of high targeting and low toxicity, providing a new candidate drug for the treatment of malignant tumors such as AML, and possesses significant clinical development value.

The invention provides application of FSP1 as a prognostic marker or a therapeutic target of non-early precursor T acute lymphocytic leukemia (non-ETP ALL), and belongs to the technical field of biological medicine. The invention discovers that the high expression of the coding gene AIFM2 of the FSP1 protein prompts that the non-ETP ALL patient is poor in prognosis. The FSP1 is used as a therapeutic target, and the FSP1 inhibitor not only can remarkably kill non-ETP ALL cells, but also can synergistically increase the sensitivity of the non-ETP ALL cells to small-dose cytarabine (Ara-C). In addition, the FSP1 inhibitor is combined with a small dose of Ara-C, so that the infiltration proportion of non-ETP ALL cells in the spleen and bone marrow of the mouse can be obviously reduced. The AIFM2 gene and the FSP1 protein coded by the AIFM2 gene are expected to become a prognostic marker and a therapeutic target of non-ETP ALL.